Tailoring access to high cost, genetically targeted drugs.

View Abstract

Assessment of real cost effectiveness, with data linked to individual health outcomes while protecting patient privacy, is an essential challenge we need to meet.

Investigators
Abbreviation
Med. J. Aust.
Publication Date
2005-06-20
Volume
182
Issue
12
Page Numbers
607-8
Pubmed ID
15963014
Medium
Print
Full Title
Tailoring access to high cost, genetically targeted drugs.
Authors
Hall WD, Ward R, Liauw WS, Lu CY, Brien JA